glp 1 drugs and autoimmune disease How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments Analysis of hundreds of thousands
Description
Nat Med 8, 738742 (2002)
Due to TriNetxs data sharing policies, we do not have access to individual-level data
Pathophysiol, Clin Present, Diagnosis P T
The oral GLP-1 receptor agonists market segment is anticipated to witness lucrative growth during the forecast period
Sonne, D
Studies have also shown that these drugs interact with other parts of the body, potentially reducing the risk of health conditions such as kidney disease, cardiovascular diseases, and heart attacks
